AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$KIDS

Squadron Capital LLC sold $7.8M of KIDS

Squadron Capital LLC sold 336,831 shares of ORTHOPEDIATRICS CORP (KIDS) at an average of $23.04 ($23.04–$23.10, $7.76M total) across 2 trades over 2026-08-28 to 2026-09-01. Filed jointly with Squadron Capital Holdings LLC (10% owner).

Original reporting
SEC EDGAR · Squadron Capital LLC, Squadron Capital Holdings LLC
Published Sep 1, 2026, 10:48 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 1, 2026, 11:33 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$KIDS
Neutral
medium confidence
Mentioned
$KIDS
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KIDSNeutralLow
01

Why it matters

The disclosed sale provides fresh data on insider holdings, useful for short‑term positioning.

02

Market read

The filing offers a new data point for traders monitoring insider activity in KIDS.

03

What to watch

Squadron Capital's remaining 6.5M shares still represent a large influence; the sale may be a routine liquidity move.

Relevance 6/10Novelty 6/10Timing: filing released after market close on Sep 1, 2026

Background

Form 4 filings disclose insider transactions; they are primary sources for ownership changes.

Company-level read

Ticker impact

$KIDSNeutralMedium confidence
Context

Squadron Capital LLC sold 336,831 shares of Orthopedics Corp (KIDS) for $7.76M in an open‑market transaction filed on Sep 1, 2026.

Expected impact

Potential modest downward pressure as a 10% owner exits a portion of its position.

Evidence & confidence

A $7.8M sale by a 10% owner signals possible portfolio rebalancing; market reaction likely limited given the remaining large stake.

Market effects

Sector

Minimal impact on the orthopedics device sector; insider sales are routine.

Regional

No significant regional effect.

Global

Limited to investors tracking KIDS.

Counterpoint

What could challenge this read

The sale could be a signal of upcoming negative news, suggesting a short opportunity.

Key entities

  • Company
    Orthopedics Corp

    Public medical device company trading under ticker KIDS.

  • Investor
    Squadron Capital LLC

    10% owner of Orthopedics Corp filing the sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

KIDS insider trading history →

Related articles

$GMABHighAI 8/10

Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%

Genmab (GMAB) shares rose 33% after reporting positive Phase 3 results for its cancer drug. Pulmonx (LUNG) and Axogen (AXGN) shares gained over 30% on strong quarterly results. OrthoPediatrics (KIDS) and Replimune (REPL) also reported improved financials, driving their stock prices up. Specific financial data and guidance were provided by each company.

rttnews.com
$KIDSMed

OrthoPediatrics Corp (KIDS) (Q3 2026) Earnings Call Highlights: Record Revenue and Raised Guidance

OrthoPediatrics Corp (KIDS) reported Q3 2026 revenue growth and raised guidance, despite increased sales expenses and gross margin pressure. The company expects Q4 revenue of roughly $69 million, with CEO David Bailey noting a conservative approach to guidance. International growth was tempered by Brazil headwinds, and the company remains unprofitable with a GAAP net loss per share of $0.25.

finance.yahoo.com
$KIDSMed

OrthoPediatrics Q3 Earnings Call Highlights

OrthoPediatrics (KIDS) reported Q3 revenue growth, with scoliosis revenue up 18% to $19.2M. The company surpassed 1,000 PNP tibial nail implantations and plans a full commercial release for PNP Retrograde in mid-2027. OPSB segment grew over 20%, with 60+ clinics. Gross margin remained at 74%, while GAAP net loss narrowed to $0.25 per share. The company raised full-year 2026 revenue guidance to $270M-$273M and expects positive free cash flow in 2027.

finance.yahoo.com
$KIDSHighAI 8/10

OrthoPediatrics (KIDS) Q3 2026 Earnings Call Transcript

OrthoPediatrics (KIDS) reported Q3 2026 revenue of $727M, up 19% YoY, and raised full-year guidance to $270M-$273M. Growth was driven by legacy products, implant demand, and international sales. The company highlighted progress in its innovation super cycle, with new products like 3P Hip, Traxeo, and VerteGlide contributing to performance. Adjusted EBITDA and free cash flow were record highs, with plans to maintain positive cash flow in 2027.

finance.yahoo.com